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Introduction
Dengue virus (DENV) is a self-limiting illness in tropical and subtropical regions around the
globe caused by four closely related, but distinct, virus serotypes (DENV-1, -2, -3, and -4) that
are transmitted among humans by mosquitoes, primarily Aedes aegypti [1]. Approximately 4
billion people living in more than 128 countries are at risk of infection [2]. Each year there are
an estimated 400 million new infections, of which about 100 million manifest as apparent ill-
ness [3]. The outcome of human infections ranges from asymptomatic to mild illness to severe,
life-threatening disease [4]. DENV not only causes more human morbidity and mortality than
any other arthropod-borne virus but it is also a growing public health threat. There has been a
dramatic 4-fold increase in dengue cases between 1990–2013 and dengue continues to expand
in geographic range [2,3,5,6].
Presently, vector control is the primary means for preventing dengue [7]. Several vaccine
constructs are in clinical trials and initial results are encouraging [8]; recently licensure was
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granted for the Sanofi Pasteur vaccine in Mexico, Brazil, and the Philippines [9]. A few well-doc-
umented successes indicate that, when rigorously applied, vector control can reduce dengue.
The advent of DDT in 1947 led to a hemisphere-wide program in the 1950s and 1960s across
Central and South America that dramatically reduced Ae. aegypti populations, resulting in
impressive reductions in yellow fever and dengue [10]. During the 1970s–1980s [11] and the
1980s–1990s [12], respectively, Singapore and Cuba successfully used vector control and larval
source reduction to reduce the force of DENV infection (i.e., per capita risk of human infection
[13]) and, thus, disease. Recent trials of indoor residual spraying [14] and indoor space spraying
[15] appeared to reduce human DENV infections. Regrettably, these control achievements were
rare and ultimately transient. Dengue reinvaded Latin America after the Ae. aegypti eradication
campaign ended, rebounded in Singapore and Cuba after 20 and 16 years of successful control,
respectively, and is increasingly being reported in Africa due to improved surveillance [16].
Although the concept of dengue vector control seems straightforward, successful broad-
scale application has been difficult to achieve and even harder to sustain [17]. In most settings,
dengue vector control failed to prevent epidemics and it is not slowing expansion of the virus’s
geographic range [3,17,18]. Unsuccessful control programs are often attributed to inadequate
responses to a robust virus transmission system. Outbreaks may occur due to combinations of
risk factors, including expanding Ae. aegypti populations, virus and mosquito dispersal via
extensive human travel networks, weak vector control infrastructure, lack of resources to
mount effective interventions, lack of political will, and ineffective implementation of existing
tools and strategies [17,19]. A recent review concluded that dengue vector control can be effec-
tive, but only when implementation is expedient, comprehensive, and sustained [7].
Despite these major challenges, there is growing interest in combining vector control with
vaccination once a dengue vaccine becomes widely available, which recognizes that one inter-
vention is insufficient to effectively reduce the burden of disease. Theoretically, a dengue vac-
cine could elevate herd immunity, making it easier to sustain the effects of vector control on
virus transmission. Similarly, vector control could lower the force of DENV infection, making
it easier to achieve vaccine delivery goals [20]. Results from studies with malaria [21,22] and
lymphatic filariasis [23] support the impact of simultaneously targeting vectors and pathogens.
The next critical step is selecting vector control strategies that are best suited for combining
with a vaccine. Selection criteria will likely depend on local dengue ecologies. Some funding
agencies are responding by enabling investigators and developers to carry out quantitative and
epidemiologic assessments of novel approaches, e.g., release ofWolbachia-infected Ae. aegypti
[24,25], spatial repellents and vapor active insecticides [26,27], and enhanced community
mobilization [28] as part of early-phase intervention evaluations [24]. Surprisingly, most exist-
ing dengue vector control strategies (e.g., larvicides and outdoor versus indoor insecticide
space spraying) have not been robustly evaluated for impact on reducing human infection and
disease [29,30]. Some trials have evaluated entomological impact [31], but reductions in mos-
quito populations do not correlate well with predictable reductions in dengue disease [20,32].
Along with underpowered and inefficient control responses, the fact that current dengue vector
control tools and strategies lack quantitative evidence of efficacy from field trials helps explain
why contemporary control programs fail more often than they succeed.
A Partnership for Dengue Control-sponsored workshop was convened to begin to address
this gap [33]. A panel of international experts identified the vector control tools currently avail-
able that may have the highest probability of success in reducing dengue and field trial experi-
mental design attributes necessary to assess their efficacy. Although vaccines will likely be
implemented concurrently with vector control, before that can be done epidemiological trials
are needed to quantify the protective efficacy of vector control interventions alone. Results will
provide a benchmark for subsequent trials in which combinations of interventions are assessed.
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This approach builds on recent calls for increased rigor in the design of vector control studies
[34] with an emphasis on dengue. In addition to benefiting dengue control programs, the
results of the proposed trial described herein will be relevant for prevention of other Ae.
aegypti-borne viral infections of increasing public health importance, such as chikungunya
[35] and Zika [36] viruses.
Dengue Vector Control Experimental Design Considerations
Ecological Complexities
Aedes aegypti will be the primary target of our intervention. Other mosquito species such as Aedes
albopictus and Aedes polynesiensis can play secondary roles in DENV transmission in specific geo-
graphic areas [37], but a trial site where Ae. aegypti is the only vector species present is desirable
to simplify interpretation of trial results. Given the overlapping distribution of Ae. aegypti and
other vectors of DENV, especially Ae. albopictus, if this is not achievable, the difference in ecology
across the species present must be taken into account when selecting control methods, interven-
tion application locations, and in the interpretation of results. If a site where only Ae. aegypti is
present is identified, trials may need to be repeated where other vector species are present.
DENV transmission is local, focal, heterogeneous, and highly efficient [38,39]. Transmis-
sion is facilitated by Ae. aegypti, which live in relatively low densities in close association with
humans and seldom fly farther than 100 m [40]. Transmission foci are connected at short dis-
tances by a combination of human and mosquito movement patterns and at longer distances
by human movement alone [38,41]. Clusters of mosquitoes and the houses they infest (high-
density hotspots) are highly focal, seldom larger than 30 m, and, even though they can consis-
tently be detected, they are temporally unstable, i.e., fine-scale mosquito abundance is continu-
ally shifting across time and space [42]. Because Ae. aegypti is a day-biting mosquito, people
are at risk of infection both in their homes and when they leave home. We therefore recom-
mend (1) accounting for human movement in a cluster-randomized controlled trial (RCT)
study design by either applying means to measure movement patterns during the follow-up
period or focusing on a least mobile section of the population and (2) conducting intervention
trials in areas with historically high levels of human infection rather than attempting to identify
and attack mosquito hotspots.
Possible Control Tools
Given Ae. aegypti’s peri-domestic habits, key candidate tools for vector control are those based
on the use of long-lasting formulations of synthetic pyrethroids applied to walls, curtains, win-
dow screens, and water container covers [7]. Reduction of larval sources through either con-
tainer removal or applications of insecticides or biological agents can decrease adult mosquito
production [31], but mosquitoes often exploit cryptic containers that remain untreated without
extensive insecticide fogging. To be most effective, larval control needs to be combined with
methods targeting adult mosquitoes [7]. Recent evidence suggests that insecticide-treated cur-
tains, window screens, and covers on water-holding containers can reduce Ae. aegypti densities
in and around treated areas [43–45], indicating that these tools should be considered in an inte-
grated approach. Innovative vector control tools that are currently being evaluated for malaria
should be explored for dengue.
Defining Impact
The protective efficacy (PE) of a treatment relates the risk of infection within a group that
receives the treatment to that of an untreated control group (see Fig 1). During the initiation of
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the trial, special messaging will be used to maximize the participation rate. By accounting accu-
rately for individuals (or homes) within treatment areas that decline to participate in the trial,
but still provide data on infection status, the relative direct and indirect effects of the trial can
be calculated (Fig 1). Classical models originally developed for malaria [46] and subsequently
applied to other mosquito-borne pathogens [47] offer a range of metrics for intervention trials
(e.g., vectorial capacity, entomological inoculation rate, and basic reproductive number [48])
and a means for mathematically connecting those metrics with other measurable outcomes
(e.g., attack rates and the force of infection [49]). These relatively simple mathematical associa-
tions offer an effective way to explore the expected relative impacts of an intervention with a
given metric, e.g., a 50% reduction in larval habitats can lead to a 75% reduction in vectorial
capacity [50]. After empirically-driven estimates of the impact of control strategies have been
calculated from an RCT, the mathematical form of these dynamics will help identify metrics
most likely to track transmission intensity and support the recommendation of appropriate
combinations of interventions to achieve maximum reduction in infection and disease.
Measuring Outcomes
Vector control is designed to directly impact mosquito populations. Although the primary end-
points of the proposed study are epidemiological, there are several crucial reasons why mos-
quito populations should be measured. In addition to continual testing for insecticide
resistance in adults and larvae, longitudinal monitoring of immature and adult mosquito densi-
ties are necessary to confirm that the intervention affected the mosquito population as
expected, and adult mosquito data can be used to assess the relative transmission risks inherent
in each cluster. If mosquito densities vary in space so that some locations systematically over-
Fig 1. Protective efficacy: basic definitions.
doi:10.1371/journal.pntd.0004588.g001
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004588 May 26, 2016 4 / 11
or under-produce compared to other locations, population dynamics should be characterized
before the trial begins and used to stratify randomization of treatment and control clusters.
Epidemiologic impact will be determined using three complementary approaches: longitu-
dinal cohorts, febrile surveillance, and geographic clusters. Seroconversion by participants in
prospective longitudinal cohorts is one way to accurately detect differences in human DENV
infection and relative risk of infection [24,51]. Identifying seroconversions to tertiary or quater-
nary infections is difficult, thus a pediatric cohort in endemic settings would be advantageous
to maximize transmission detection (i.e., people who enter the study as immunologically naïve
or have a monotypic antibody response) and minimize the potential for movement between
treatment and control study arms. Serostatus will be monitored to determine if there was more
than one infection between any two tests. At locations where more than one flavivirus is trans-
mitted (e.g., yellow fever, Japanese encephalitis, Zika) or where people have been vaccinated
against other flaviviruses (e.g., yellow fever, Japanese encephalitis), interpretation of DENV
seroconversions will need to account for cross-immunity to closely related viruses. If a trial is
conducted in concert with, or soon after, administration of a DENV vaccine, the design can
include a surrogate endpoint of clinically apparent DENV infections that are virologically con-
firmed, similar to what has been done in recent dengue vaccine trials [52]. A serologic-based
endpoint could be used for vaccinated populations if, in the future, new assays are developed
that can differentiate the immune response to vaccination versus a natural DENV exposure.
Within a subset of identified neighborhood clusters, participants will be recruited for a lon-
gitudinal cohort. Routine febrile surveillance consisting of one to three visits per household per
week of people living near cohort participants will allow longitudinal comparisons of people
with documented dengue illness [38]. Geographic cluster studies that screen people living
within a designated radius (~100m) of a person with a laboratory-diagnosed DENV infection
(the index case) will measure variation in fine-scale spatial patterns of DENV transmission
[24]. Depending on how movement is accounted for or incorporated into the trial design,
cohort sample size estimates will be in the range of 2,000 to 3,000 participants [51], with at
least five times that number under febrile surveillance [38]. The number of clusters in the study
will depend on background transmission, local herd immunity, anticipated effect size of the
intervention, between cluster variation, and logistics capacity.
Design and Analysis
Given the diffusive effect of mosquito dispersal on transmission risk, vector control trials typi-
cally employ a cluster RCT study design [53] in which communities are randomly allocated to
intervention or control arms [34]. One of the largest challenges with measuring the impact of
vector control on dengue transmission, as opposed to other mosquito-borne diseases such as
malaria, is that dengue vectors bite during the day. People who live within a cluster assigned to
receive the intervention may, therefore, spend a considerable amount of their day at risk of infec-
tion in untreated areas. Conversely, those living in untreated areas may move into treated areas
during their daytime activities. To estimate accurately the effectiveness of vector control on den-
gue transmission, information on the movement patterns of individuals within the treatment
and control arms is needed to estimate individual-level time under coverage. One way to limit
the effect of human movement is to have clusters that include large geographic areas and to
enroll children who may not be as mobile as adults, although this may be operationally difficult
to achieve and expensive. The effectiveness of a community-applied strategy, as often occurs in
vector control, will likely only be fully felt by those who never leave the treated area (see Fig 2).
As an individual spends increasingly more time in locations where transmission continues
unhindered, their individual risk of infection recovers to background levels. By incorporating
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Fig 2. Estimating protective efficacy when consideringmovement out of coverage areas.
doi:10.1371/journal.pntd.0004588.g002
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individual-level time under coverage in analyses, the maximum possible effect (as well as the
average predicted effects) of the intervention can be estimated (see Fig 2). When possible, if
movement patterns systematically differ across cluster arms, random assignment of clusters to
treatment versus control should be stratified by movement level, much like cluster stratification
using baseline incidence or prevalence rates commonly employed in malaria trials [54].
An alternate design to the “dose-response” approach described above would focus on only
those individuals who move the least. Initial movement surveys may identify a sub-population
that is less mobile, i.e., young children. Clusters can then be defined based on movement range
and design, and analysis can use the standard metrics described in Fig 1. This approach might
necessitate large numbers of participants in clusters if fewer susceptible individuals qualify for
enrollment. On the other hand, this approach directly assesses treatment with a more rigorous,
but potentially less valid, assumption of equal exposure to all those who are treated. The choice
as to which study design is optimal will likely be context and resource dependent. If the more
rigorous option is taken, movement data and analyses metrics in Fig 2 can be applied as a sec-
ondary endpoint.
Site Selection
Trial site selection will follow a detailed process of criteria evaluation to identify locations with
the capacity to rigorously assess the intervention [34]. DENV must be endemic with existing
information on transmission intensity and local Ae. aegypti population dynamics. Infrastruc-
ture and trained personnel must be in place for measuring entomological and epidemiological
outcomes. Community engagement of study participants should be ongoing throughout the
entire trial period. Public opinion and compliance will be key for a successful assessment. A
framework for communicating with stakeholders has been developed for evaluating genetically
modified mosquitoes, a strategy in which public opinion and compliance are challenging and
from which trials using other vector control interventions could benefit [55].
Preliminary studies on opinions about vector control will help inform the most effective
strategy. Local Ae. aegypti populations will be screened for resistance to determine available
insecticides for each potential site. Baseline virology and vector sampling should be carried out
for one year before interventions and intervention should last for at least two transmission sea-
sons to account for inter-annual variation in transmission and mosquito population densities.
It will be important for funders to understand the return on investment of longer duration tri-
als for informed decision-making.
Concerns
Insecticide Resistance
Insecticide resistance is a particularly worrisome challenge for dengue prevention because
most dengue vector control strategies rely heavily on the use of chemical control. The resis-
tance status of the target vector population should be taken into consideration when designing
interventions to ensure that the product used will not only achieve maximum impact but have
sustained effects throughout anticipated DENV transmission cycles. Resistance should be
monitored throughout the trial, e.g., by knockdown resistance (kdr) andWHO bioassays [56].
Given the extended duration of continual insecticide application, options to mitigate selection
pressure should be determined prior to intervention roll-out to avoid, mitigate, and minimize
the development of resistance associated with the specific interventions. The degree to which
insecticide resistance compromises dengue vector control efficacy remains largely unknown,
but should not be underestimated given that the most cost-effective vector control tools rely
heavily on the use of a highly limited number of public health insecticides [57].
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Ethics
The ethical, social, and cultural framework for trial site selection outlined by Lavery et al. [58]
will be applied. As such, community authorization and participation is a priority for site selec-
tion and conducting a meaningful trial. After the regulatory process has been defined, thorough
ethical evaluation of the study design will be carried out, including the possible use of a placebo
if no established intervention is used. During the trial, government and public health dengue
control programs must be allowed to conduct routine vector control activities because this can-
not ethically be prevented or hindered. Trial management should follow fundamentals used for
Good Clinical Practice, including standard operating procedures; a trial steering committee;
convening or engaging data monitoring, safety, and ethics committees; a dedicated trial moni-
tor; and that the analytical plan should be finalized before commencement of the trial.
Recommendation
The “local and focal” nature of DENV transmission and the often large variation in transmis-
sion patterns from year to year, combined with the short-range dispersal of the day-biting vec-
tor Ae. aegypti, create a challenging context for evaluating the effectiveness of any dengue
vector control intervention. Detecting a causal relationship between entomological impact and
a reduction in dengue transmission intensity requires careful trial design. Within the design of
an RCT, it is important to account for human movement patterns. If human movement is
ignored, a successful intervention may appear to have failed. Ignoring human movement dur-
ing study design considerations would require an artificial increase in the expected effective-
ness to achieve adequate power because every individual in a treatment cluster will be
predicted to have the “maximum” effect. Ignoring human movement during analysis would
almost certainly reduce the ability to detect a significant effect of the intervention due to spill-
over of “treated” individuals into areas without protection. Potential confounding factors such
as the development of insecticide resistance over the course of the trial or an unanticipated lack
of residual effect of the intervention could directly compromise trial outcomes and should be
closely monitored. Building a bridge between dengue control experiences and those of other
vector-borne pathogens, especially Plasmodium, may accelerate advancement of control tech-
niques across multiple diseases.
Conclusions
Very few vector control tools for any mosquito-borne pathogen have been assessed in
Cochrane-style reviews, which are generally considered the most rigorous assessment of health
interventions, largely due to design flaws [34]. For dengue, there are very few published studies
[28] and even fewer studies that formally assess the impact of existing insecticide-based strate-
gies on dengue. Although there is progress in the development of a dengue vaccine, it is likely for
the foreseeable future that integrating vector control and vaccination will be necessary [33]. Inte-
grated Vector Management is endorsed by the World Health Organization for the control of
dengue and other vector-borne diseases [57]. Insecticides cannot be distributed and dissemi-
nated in vast quantities across broad geographic areas without concern for ecological and envi-
ronmental impact. Subjecting any population to continued exposure to insecticides requires
precise estimates of both the costs (economic and environmental) and the public health benefits.
As dengue’s global burden grows, the need for proven effective vector control options will
increase. We argue that quantifying the epidemiological impact of any vector control interven-
tion on DENV transmission will require assessments of human movement. We propose two
options: cluster sizes can be enlarged and maximum age of participants can be reduced until
protection is approximately uniformly felt by all those who are intended to be treated. This
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may, however, greatly increase required resources for already economically challenging trials.
The alternative option is more efficient, but comes with some cost in rigor. As described in Fig
2, human movement patterns can be explicitly incorporated into the calculations for protective
efficacy, with movement either inferred from simple geographic-based movement kernels or
explicitly estimated by extrapolating the movement patterns of a sub-population within each
cluster. Using either approach, intervention trials can provide robust and meaningful informa-
tion. Insights from such trials will help guide the scaling up of effective dengue control strate-
gies, whether vector control alone or in combination with vaccines, and will be applicable to
other Ae. aegypti-borne viral infections of current public health concern, such as chikungunya
and Zika viruses.
Acknowledgments
Disclaimer: One of the authors (JH) is staff of the World Health Organization. The views
expressed in this publication do not necessarily represent the decisions, policy or views of the
World Health Organization.
References
1. Simmons CP, Farrar JJ, van Vinh Chau N, Wills B. Dengue. New England Journal of Medicine. 2012;
366(15):1423–32. doi: 10.1056/NEJMra1110265 PMID: 22494122
2. Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG, et al. Refining the global spatial
limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis. 2012; 6(8):
e1760. doi: 10.1371/journal.pntd.0001760 PMID: 22880140
3. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and
burden of dengue. Nature. 2013; 496(7446):504–7. doi: 10.1038/nature12060 PMID: 23563266
4. St John AL, Rathore AP, Raghavan B, Ng M-L, Abraham SN. Contributions of mast cells and vasoac-
tive products, leukotrienes and chymase, to dengue virus-induced vascular leakage. eLife. 2013; 2:
e00481. doi: 10.7554/eLife.00481 PMID: 23638300
5. Messina JP, Brady OJ, Pigott DM, Brownstein JS, Hoen AG, Hay SI. A global compendium of human
dengue virus occurrence. Scientific Data. 2013; 1:140004-.
6. NgM, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national
prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis
for the Global Burden of Disease Study 2013. The Lancet. 2014; 384(9945):766–81.
7. Achee NL, Gould F, Perkins TA, Reiner RC Jr, Morrison AC, Ritchie SA, et al. A critical assessment of
vector control for dengue prevention. PLoS Negl Trop Dis. 2015; 9(5):e0003655. doi: 10.1371/journal.
pntd.0003655 PMID: 25951103
8. Schwartz LM, Halloran ME, Durbin AP, Longini IM. The dengue vaccine pipeline: Implications for the
future of dengue control. Vaccine. 2015; 33(29):3293–8. doi: 10.1016/j.vaccine.2015.05.010 PMID:
25989449
9. Science AAftAo. News at a glance. Science. 2015; 350(6267):1446–8.
10. Monath TP. Dengue: the risk to developed and developing countries. Proceedings of the National
Academy of Sciences. 1994; 91(7):2395–400.
11. Ooi E-E, Goh K-T, Gubler DJ. Dengue prevention and 35 years of vector control in Singapore. Emerg-
ing Infectious Diseases. 2006; 12(6):887–93. PMID: 16707042
12. Kourí G, Guzmán MG, Valdés L, Carbonel I, del Rosario D, Vazquez S, et al. Reemergence of dengue
in Cuba: a 1997 epidemic in Santiago de Cuba. Emerging Infectious Diseases. 1998; 4(1):89. PMID:
9454563
13. Egger M, Smith GD, Altman D. Systematic reviews in health care: meta-analysis in context: JohnWiley
& Sons; 2008.
14. Vazquez-Prokopec GM, Kitron U, Montgomery B, Horne P, Ritchie SA. Quantifying the spatial dimen-
sion of dengue virus epidemic spread within a tropical urban environment. PLoS Negl Trop Dis. 2010; 4
(12):e920. doi: 10.1371/journal.pntd.0000920 PMID: 21200419
15. Stoddard ST, Wearing HJ, Reiner RC Jr, Morrison AC, Astete H, Vilcarromero S, et al. Long-term and
seasonal dynamics of dengue in Iquitos, Peru. PLoS Negl Trop Dis. 2014; 8(7):e3003. doi: 10.1371/
journal.pntd.0003003 PMID: 25033412
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004588 May 26, 2016 9 / 11
16. Amarasinghe A, Kuritsk J, Letson GW, Margolis HS. Dengue virus infection in Africa. Emerging Infec-
tious Diseases. 2011; 17(8):1349–54. doi: 10.3201/eid1708.101515 PMID: 21801609
17. Morrison AC, Zielinski-Gutierrez E, Scott TW, Rosenberg R. Defining challenges and proposing solu-
tions for control of the virus vector Aedes aegypti. PLoS Med. 2008; 5(3):e68. doi: 10.1371/journal.
pmed.0050068 PMID: 18351798
18. Gubler DJ. Prevention and control of Aedes aegypti-borne diseases: lesson learned from past suc-
cesses and failures. AsPac J Mol Biol Biotechnol. 2011; 19(3):111–4.
19. Kraemer MU, Sinka ME, Duda KA, Mylne AQ, Shearer FM, Barker CM, et al. The global distribution of
the arbovirus vectors Aedes aegypti and Ae. albopictus. Elife. 2015; 4:e08347. doi: 10.7554/eLife.
08347 PMID: 26126267
20. Scott TW, Morrison AC. Longitudinal field studies will guide a paradigm shift in dengue prevention. Vec-
tor Biology, Ecology and Control: Springer; 2010. p. 139–61.
21. Bhatt S, Weiss D, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et al. The effect of malaria control
on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015; 526:207–11. doi: 10.1038/
nature15535 PMID: 26375008
22. Organization WH. World malaria report 2013: World Health Organization; 2014.
23. Reimer LJ, Thomsen EK, Tisch DJ, Henry-Halldin CN, Zimmerman PA, Baea ME, et al. Insecticidal
bed nets and filariasis transmission in Papua New Guinea. New England Journal of Medicine. 2013;
369(8):745–53. doi: 10.1056/NEJMoa1207594 PMID: 23964936
24. Duong V, Lambrechts L, Paul RE, Ly S, Lay RS, Long KC, et al. Asymptomatic humans transmit den-
gue virus to mosquitoes. Proceedings of the National Academy of Sciences. 2015; 112(47):14688–93.
25. Hoffmann A, Montgomery B, Popovici J, Iturbe-Ormaetxe I, Johnson P, Muzzi F, et al. Successful
establishment of Wolbachia in Aedes populations to suppress dengue transmission. Nature. 2011; 476
(7361):454–7. doi: 10.1038/nature10356 PMID: 21866160
26. Achee NL, Bangs MJ, Farlow R, Killeen GF, Lindsay S, Logan JG, et al. Spatial repellents: from discov-
ery and development to evidence-based validation. Malaria Journal. 2012; 11(164):10.1186.
27. Ritchie SA, Devine GJ. Confusion, knock-down and kill of Aedes aegypti using metofluthrin in domestic
settings: a powerful tool to prevent dengue transmission. Parasite & Vectors. 2013; 6:262–80.
28. Andersson N, Nava-Aguilera E, Arosteguí J, Morales-Perez A, Suazo-Laguna H, Legorreta-Soberanis
J, et al. Evidence based community mobilization for dengue prevention in Nicaragua and Mexico
(Camino Verde, the GreenWay): cluster randomized controlled trial. BMJ. 2015; 351:h3267. doi: 10.
1136/bmj.h3267 PMID: 26156323
29. Pilger D, De Maesschalck M, Horstick O, San Martin JL. Dengue outbreak response: documented
effective interventions and evidence gaps. TropIKA net. 2010; 1(1):0-.
30. Esu E, Lenhart A, Smith L, Horstick O. Effectiveness of peridomestic space spraying with insecticide on
dengue transmission; systematic review. Tropical Medicine & International Health. 2010; 15(5):619–
31.
31. Erlanger T, Keiser J, Utzinger J. Effect of dengue vector control interventions on entomological parame-
ters in developing countries: a systematic review and meta-analysis. Medical and veterinary entomol-
ogy. 2008; 22(3):203–21. doi: 10.1111/j.1365-2915.2008.00740.x PMID: 18816269
32. Bowman LR, Runge-Ranzinger S, McCall P. Assessing the relationship between vector indices and
dengue transmission: a systematic review of the evidence. PLoS Negl Trop Dis. 2014; 8(5):e2848. doi:
10.1371/journal.pntd.0002848 PMID: 24810901
33. Gubler DJ. The partnership for dengue control-A new global alliance for the prevention and control of
dengue. Vaccine. 2015; 33(10):1233. doi: 10.1016/j.vaccine.2015.01.002 PMID: 25597939
34. Wilson AL, Boelaert M, Kleinschmidt I, Pinder M, Scott TW, Tusting LS, et al. Evidence-based vector
control? Improving the quality of vector control trials. Trends in Parasitology. 2015; 31(8):380–90. doi:
10.1016/j.pt.2015.04.015 PMID: 25999026
35. Rolph MS, Foo SS, Mahalingam S. Emergent chikungunya virus and arthritis in the Americas. The Lan-
cet Infectious Diseases. 2015; 15(9):1007–8. doi: 10.1016/S1473-3099(15)00231-5 PMID: 26333330
36. Musso D, Cao-Lormeau VM, Gubler DJ. Zika virus: following the path of dengue and chikungunya?
The Lancet. 2015; 386(9990):243–4.
37. Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese
encephalitis, West Nile and dengue viruses. Nature Medicine. 2004; 10:S98–S109. PMID: 15577938
38. Stoddard ST, Forshey BM, Morrison AC, Paz-Soldan VA, Vazquez-Prokopec GM, Astete H, et al.
House-to-house human movement drives dengue virus transmission. Proceedings of the National
Academy of Sciences. 2013; 110(3):994–9.
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004588 May 26, 2016 10 / 11
39. Yoon I-K, Getis A, Aldstadt J, Rothman AL, Tannitisupawong D, Koenraadt CJ, et al. Fine scale spatio-
temporal clustering of dengue virus transmission in children and Aedes aegypti in rural Thai villages.
PLoS Negl Trop Dis. 2012; 6(7):e1730. doi: 10.1371/journal.pntd.0001730 PMID: 22816001
40. Harrington LC, Scott TW, Lerdthusnee K, Coleman RC, Costero A, Clark GG, et al. Dispersal of the
dengue vector Aedes aegypti within and between rural communities. The American Journal of Tropical
Medicine and Hygiene. 2005; 72(2):209–20. PMID: 15741559
41. Liebman KA, Stoddard ST, Morrison AC, Rocha C, Minnick S, Sihuincha M, et al. Spatial dimensions of
dengue virus transmission across interepidemic and epidemic periods in Iquitos, Peru (1999–2003).
PLoS Negl Trop Dis. 2012; 6(2):e1472. doi: 10.1371/journal.pntd.0001472 PMID: 22363822
42. LaCon G, Morrison AC, Astete H, Stoddard ST, Paz-Soldan VA, Elder JP, et al. Shifting patterns of
Aedes aegypti fine scale spatial clustering in Iquitos, Peru. PLoS Negl Trop Dis. 2014; 8(8):e3038. doi:
10.1371/journal.pntd.0003038 PMID: 25102062
43. Kroeger A, Lenhart A, Ochoa M, Villegas E, Levy M, Alexander N, et al. Effective control of dengue vec-
tors with curtains and water container covers treated with insecticide in Mexico and Venezuela: cluster
randomised trials. BMJ. 2006; 332(7552):1247–52. PMID: 16735334
44. Che-Mendoza A, Guillermo-May G, Herrera-Bojórquez J, Barrera-Pérez M, Dzul-Manzanilla F, Gutier-
rez-Castro C, et al. Long-lasting insecticide-treated house screens and targeted treatment of productive
breeding-sites for dengue vector control in Acapulco, Mexico. Transactions of The Royal Society of
Tropical Medicine and Hygiene. 2015; 109(2):106–15. doi: 10.1093/trstmh/tru189 PMID: 25604761
45. Manrique-Saide P, Che-Mendoza A, Barrera-Perez M, Guillermo-May G, Herrera-Bojorquez J, Dzul-
Manzanilla F, et al. Use of Insecticide-Treated House Screens to Reduce Infestations of Dengue Virus
Vectors, Mexico. Emerging Infectious Diseases. 2015; 21(2):308. doi: 10.3201/eid2102.140533 PMID:
25625483
46. Smith DL, Battle KE, Hay SI, Barker CM, Scott TW, McKenzie FE. Ross, Macdonald, and a theory for
the dynamics and control of mosquito-transmitted pathogens. PLoS Pathog. 2012; 8(4):e1002588. doi:
10.1371/journal.ppat.1002588 PMID: 22496640
47. Reiner RC, Perkins TA, Barker CM, Niu T, Chaves LF, Ellis AM, et al. A systematic review of mathemat-
ical models of mosquito-borne pathogen transmission: 1970–2010. Journal of The Royal Society Inter-
face. 2013; 10(81):20120921.
48. Smith DL, McKenzie FE. Statics and dynamics of malaria infection in Anopheles mosquitoes. Malaria
Journal. 2004; 3(1):13.
49. Smith DL, McKenzie FE, Snow RW, Hay SI. Revisiting the basic reproductive number for malaria and
its implications for malaria control. PLoS Biol. 2007; 5(3):e42. PMID: 17311470
50. Smith DL, Perkins TA, Tusting LS, Scott TW, Lindsay SW. Mosquito population regulation and larval
source management in heterogeneous environments. PLoS ONE. 2013; 8(8):e71247. doi: 10.1371/
journal.pone.0071247 PMID: 23951118
51. Wolbers M, Kleinschmidt I, Simmons CP, Donnelly CA. Considerations in the design of clinical trials to
test novel entomological approaches to dengue control. PLoS Negl Trop Dis. 2012; 6(11).
52. Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, et al.
Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. New England Journal
of Medicine. 2015; 373(13):1195–206. doi: 10.1056/NEJMoa1506223 PMID: 26214039
53. Hayes R, Moulton L. Cluster randomized trials Boca Raton. USA: CRC Press; 2009.
54. Bache E, Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Kabwende AL, et al. Efficacy and safety of
RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final
results of a phase 3, individually randomised, controlled trial. Lancet. 2015; 386(9988).
55. Organization WH. Guidance framework for testing of genetically modified mosquitoes www.who.int/tdr/
news/2012/guidance_framework/en/index.html 2012[cited 2015 1 September].
56. Kelly-Hope L, Ranson H, Hemingway J. Lessons from the past: managing insecticide resistance in
malaria control and eradication programmes. The Lancet Infectious Diseases. 2008; 8(6):387–9. doi:
10.1016/S1473-3099(08)70045-8 PMID: 18374633
57. Organization WH, Research SPf, Diseases TiT, DiseasesWHODoCoNT, EpidemicWHO, Alert P.
Dengue: guidelines for diagnosis, treatment, prevention and control: World Health Organization; 2009.
58. Lavery JV, Harrington LC, Scott TW. Ethical, social, and cultural considerations for site selection for
research with genetically modified mosquitoes. The American Journal of Tropical Medicine and
Hygiene. 2008; 79(3):312–8. PMID: 18784220
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004588 May 26, 2016 11 / 11
